Registre, CharmanteSoares, Rodrigo Dian de Oliveira AguiarRúbio, Karina Taciana SantosSantos, Orlando David Henrique dosCarneiro, Simone Pinto2023-10-172023-10-172023REGISTRE, C. et al. A systematic review of drug-carrying nanosystems used in the treatment of leishmaniasis. ACS Infectious Diseases, v. 9, p. 423−449, 2023. Disponível em: <https://pubs.acs.org/doi/epdf/10.1021/acsinfecdis.2c00632>. Acesso em: 01 ago. 2023.2373-8227http://www.repositorio.ufop.br/jspui/handle/123456789/17584Leishmaniasis is an infectious disease responsible for a huge rate of morbidity and mortality in humans. Chemotherapy consists of the use of pentavalent antimonial, amphotericin B, pentamidine, miltefosine, and paromomycin. However, these drugs are associated with some drawbacks such as high toxicity, administration by parenteral route, and most seriously the resistance of some strains of the parasite to them. Several strategies have been used to increase the therapeutic index and reduce the toxic effects of these drugs. Among them, the use of nanosystems that have great potential as a site-specific drug delivery system stands out. This review aims to compile results from studies that were carried out using first- and second-line antileishmanial drug- carrying nanosystems. The articles referred to here were published between 2011 and 2021. This study shows the promise of effective applicability of drug-carrying nanosystems in the field of antileishmanial therapeutics, with the perspective of providing better patient adherence to treatment, increased therapeutic efficacy, reduced toxicity of conventional drugs, as well as the potential to efficiently improve the treatment of leishmaniasis.en-USrestritoNanotechnologyNanoparticlesDrug deliveryAntileishmanial drugsAntiparasiticArtigo publicado em periodicohttps://pubs.acs.org/doi/epdf/10.1021/acsinfecdis.2c00632https://doi.org/10.1021/acsinfecdis.2c00632